Preeclampsia resident survival guide: Difference between revisions
Agnesrinky (talk | contribs) |
No edit summary |
||
(34 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 0 0 10px 10px;" cellpadding="0" cellspacing="0" ; | |||
|- | |||
! style="padding: 0 5px; font-size: 85%; background: #A8A8A8" align="center" |{{fontcolor|#2B3B44|Preeclampsia Resident Survival Guide Microchapters}} | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Preeclampsia resident survival guide#Overview|Overview]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Preeclampsia resident survival guide#Causes|Causes]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Preeclampsia resident survival guide#Diagnosis|Diagnosis]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Preeclampsia resident survival guide#Treatment|Treatment]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Preeclampsia resident survival guide#Dos|Dos]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Preeclampsia resident survival guide#Don'ts|Don'ts]] | |||
|} | |||
{{WikiDoc CMG}}; {{AE}} {{RAB}} | {{WikiDoc CMG}}; {{AE}} {{RAB}} | ||
{{SK}} | {{SK}} Approach to preeclampsia , Approach to gestational hypertension with proteinuria | ||
==Overview== | ==Overview== | ||
[[Pre-eclampsia|Preeclampsia]] is primarily defined as [[gestational hypertension]] with [[proteinuria]] 300 mg or more over a 24-hour period. The pathophysiologic abnormalities of [[Pre-eclampsia|preeclampsia]] include placental [[ischemia]], generalized [[vasospasm]], abnormal [[hemostasis]] with activation of the [[coagulation]] system, vascular [[Endothelium|endothelial]] dysfunction, abnormal [[nitric oxide]] and [[lipid metabolism]], [[leukocyte]] activation and changes in various [[Cytokine|cytokines]] as well as in [[insulin]] resistance. It is important to identify those with high risk of developing [[Pre-eclampsia|preeclampsia]] during their pregnancy for better management. [[Maternal]] and [[fetal]] outcomes in [[Pre-eclampsia|preeclampsia]] depend on one or more of these factors: [[gestational age]] at onset of [[Pre-eclampsia|preeclampsia]] as well as at time of [[delivery]], the severity of the [[disease]] process, the presence of multifetal [[gestation]], and the presence of other preexisting medical conditions such as [[diabetes]], [[renal disease]], or [[Thrombophilia|thrombophilias]]. It is associated with an increased risk of [[placental abruption]], [[preterm birth]], [[Intrauterine growth restriction|fetal intrauterine growth restriction]] ([[IUGR]]), [[acute renal failure]], [[Cerebrovascular disease|cerebrovascular]] and [[cardiovascular]] complications, [[disseminated intravascular coagulation]], and maternal death. Therefore, it is necessary to diagnose [[Pre-eclampsia|preeclampsia]] early. | |||
==Causes== | ==Causes== | ||
The high risk factors of [[preeclampsia]] are | The high risk factors of [[preeclampsia]] are: | ||
* History of any [[hypertensive disease]] during a previous [[pregnancy]]. | |||
* [[Maternal]] disease such as[[chronic kidney disease]], [[autoimmune diseases]], [[diabetes]], [[chronic hypertension]]. | *History of any [[hypertensive disease]] during a previous [[pregnancy]]. | ||
Women are at moderate risk if they are | *[[Maternal]] disease such as [[chronic kidney disease]], [[autoimmune diseases]], [[diabetes]], [[chronic hypertension]]. | ||
* [[Nulliparous]] | |||
* ≥40 years of age | Women are at moderate risk if they are: | ||
* [[Body mass index]] (BMI) ≥ 35 kg/m <ref name="pmid29899139">{{cite journal |vauthors=Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S |title=Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice |journal=Hypertension |volume=72 |issue=1 |pages=24–43 |date=July 2018 |pmid=29899139 |doi=10.1161/HYPERTENSIONAHA.117.10803 |url= |issn=}}</ref> | |||
* | *[[Nulliparous]] | ||
* Multifetal [[pregnancy]] | *≥40 years of age | ||
* A [[pregnancy]] interval of more than 10 years<ref name="urlOverview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE">{{cite web |url=https://www.nice.org.uk/guidance/ng133 |title=Overview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | *Have a [[Body mass index]] (BMI) ≥ 35 kg/m <ref name="pmid29899139">{{cite journal |vauthors=Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S |title=Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice |journal=Hypertension |volume=72 |issue=1 |pages=24–43 |date=July 2018 |pmid=29899139 |doi=10.1161/HYPERTENSIONAHA.117.10803 |url= |issn=}}</ref> | ||
Additional clinical factors: | *Have a family history of [[preeclampsia]] | ||
* Raised mean arterial blood pressure before 15 | *Have a Multifetal [[pregnancy]] | ||
* Polycystic ovarian syndrome<ref name="pmid30674081">{{cite journal |vauthors=Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, Misso ML, Teede HJ, Moran LJ |title=Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression |journal=Obes Rev |volume=20 |issue=5 |pages=659–674 |date=May 2019 |pmid=30674081 |doi=10.1111/obr.12829 |url= |issn=}}</ref><ref name="pmid23800002">{{cite journal |vauthors=Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY |title=Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis |journal=Reprod Biol Endocrinol |volume=11 |issue= |pages=56 |date=June 2013 |pmid=23800002 |pmc=3737012 |doi=10.1186/1477-7827-11-56 |url= |issn=}}</ref> | *Have a A [[pregnancy]] interval of more than 10 years<ref name="urlOverview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE">{{cite web |url=https://www.nice.org.uk/guidance/ng133 |title=Overview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | ||
* Sleep disordered breathing <ref name="pmid23911687">{{cite journal |vauthors=Pamidi S, Pinto LM, Marc I, Benedetti A, Schwartzman K, Kimoff RJ |title=Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis |journal=Am J Obstet Gynecol |volume=210 |issue=1 |pages=52.e1–52.e14 |date=January 2014 |pmid=23911687 |doi=10.1016/j.ajog.2013.07.033 |url= |issn=}}</ref> | |||
* Various infections such as periodontal disease, urinary tract infections<ref name="pmid17577649">{{cite journal |vauthors=Rustveld LO, Kelsey SF, Sharma R |title=Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies |journal=Matern Child Health J |volume=12 |issue=2 |pages=223–42 |date=March 2008 |pmid=17577649 |doi=10.1007/s10995-007-0224-1 |url= |issn=}}</ref> and helicobacter pylori<ref name="pmid29388723">{{cite journal |vauthors=Bellos I, Daskalakis G, Pergialiotis V |title=Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies |journal=Int J Clin Pract |volume=72 |issue=2 |pages= |date=February 2018 |pmid=29388723 |doi=10.1111/ijcp.13064 |url= |issn=}}</ref>. | Additional clinical factors associated with preeclampsia are : | ||
* Vaginal bleeding for at least five days during pregnancy increases preeclampsia risk<ref name="pmid21474517">{{cite journal |vauthors=North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC |title=Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort |journal=BMJ |volume=342 |issue= |pages=d1875 |date=April 2011 |pmid=21474517 |pmc=3072235 |doi=10.1136/bmj.d1875 |url= |issn=}}</ref> | |||
* Use of oocyte donation has a higher risk of preeclampsia than in vitro fertilization (IVF) without oocyte donation or natural conception.<ref name="pmid27007875">{{cite journal |vauthors=Blázquez A, García D, Rodríguez A, Vassena R, Figueras F, Vernaeve V |title=Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis |journal=J Assist Reprod Genet |volume=33 |issue=7 |pages=855–63 |date=July 2016 |pmid=27007875 |pmc=4930777 |doi=10.1007/s10815-016-0701-9 |url= |issn=}}</ref><ref name="pmid26627731">{{cite journal |vauthors=Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D |title=Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis |journal=Am J Obstet Gynecol |volume=214 |issue=3 |pages=328–39 |date=March 2016 |pmid=26627731 |doi=10.1016/j.ajog.2015.11.020 |url= |issn=}}</ref> | *Raised mean arterial [[blood pressure]] before 15 weeks [[gestation]]<ref name="pmid21474517">{{cite journal |vauthors=North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC |title=Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort |journal=BMJ |volume=342 |issue= |pages=d1875 |date=April 2011 |pmid=21474517 |pmc=3072235 |doi=10.1136/bmj.d1875 |url= |issn=}}</ref> | ||
*[[Polycystic ovarian syndrome]]<ref name="pmid30674081">{{cite journal |vauthors=Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, Misso ML, Teede HJ, Moran LJ |title=Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression |journal=Obes Rev |volume=20 |issue=5 |pages=659–674 |date=May 2019 |pmid=30674081 |doi=10.1111/obr.12829 |url= |issn=}}</ref><ref name="pmid23800002">{{cite journal |vauthors=Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY |title=Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis |journal=Reprod Biol Endocrinol |volume=11 |issue= |pages=56 |date=June 2013 |pmid=23800002 |pmc=3737012 |doi=10.1186/1477-7827-11-56 |url= |issn=}}</ref> | |||
*[[Sleep disordered]] [[breathing]] <ref name="pmid23911687">{{cite journal |vauthors=Pamidi S, Pinto LM, Marc I, Benedetti A, Schwartzman K, Kimoff RJ |title=Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis |journal=Am J Obstet Gynecol |volume=210 |issue=1 |pages=52.e1–52.e14 |date=January 2014 |pmid=23911687 |doi=10.1016/j.ajog.2013.07.033 |url= |issn=}}</ref> | |||
*Various infections such as [[periodontal]] disease,[[ urinary tract infections]]<ref name="pmid17577649">{{cite journal |vauthors=Rustveld LO, Kelsey SF, Sharma R |title=Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies |journal=Matern Child Health J |volume=12 |issue=2 |pages=223–42 |date=March 2008 |pmid=17577649 |doi=10.1007/s10995-007-0224-1 |url= |issn=}}</ref> and [[helicobacter pylori]]<ref name="pmid29388723">{{cite journal |vauthors=Bellos I, Daskalakis G, Pergialiotis V |title=Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies |journal=Int J Clin Pract |volume=72 |issue=2 |pages= |date=February 2018 |pmid=29388723 |doi=10.1111/ijcp.13064 |url= |issn=}}</ref>. | |||
*[[Vaginal bleeding]] for at least five days during [[pregnancy]] increases preeclampsia risk<ref name="pmid21474517">{{cite journal |vauthors=North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC |title=Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort |journal=BMJ |volume=342 |issue= |pages=d1875 |date=April 2011 |pmid=21474517 |pmc=3072235 |doi=10.1136/bmj.d1875 |url= |issn=}}</ref> | |||
*Use of [[oocyte]] donation has a higher risk of [[preeclampsia]] than in vitro fertilization ([[IVF]]) without [[oocyte]] donation or natural [[conception]].<ref name="pmid27007875">{{cite journal |vauthors=Blázquez A, García D, Rodríguez A, Vassena R, Figueras F, Vernaeve V |title=Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis |journal=J Assist Reprod Genet |volume=33 |issue=7 |pages=855–63 |date=July 2016 |pmid=27007875 |pmc=4930777 |doi=10.1007/s10815-016-0701-9 |url= |issn=}}</ref><ref name="pmid26627731">{{cite journal |vauthors=Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D |title=Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis |journal=Am J Obstet Gynecol |volume=214 |issue=3 |pages=328–39 |date=March 2016 |pmid=26627731 |doi=10.1016/j.ajog.2015.11.020 |url= |issn=}}</ref> | |||
=====Common Causes===== | =====Common Causes===== | ||
Common | Common causes of [[preeclampsia]] include [[uteroplacental]] [[ischemia]] and [[genetic predisposition]] due to the following:<ref name="LyeBloise2013">{{cite journal|last1=Lye|first1=P.|last2=Bloise|first2=E.|last3=Dunk|first3=C.|last4=Javam|first4=M.|last5=Gibb|first5=W.|last6=Lye|first6=S.J.|last7=Matthews|first7=S.G.|title=Effect of oxygen on multidrug resistance in the first trimester human placenta|journal=Placenta|volume=34|issue=9|year=2013|pages=817–823|issn=01434004|doi=10.1016/j.placenta.2013.05.010}}</ref><ref name="MayrinkCosta2018">{{cite journal|last1=Mayrink|first1=J.|last2=Costa|first2=M. L.|last3=Cecatti|first3=J. G.|title=Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction|journal=The Scientific World Journal|volume=2018|year=2018|pages=1–9|issn=2356-6140|doi=10.1155/2018/6268276}}</ref> | ||
* The formation of [[atheromatous plaques]] and [[fibrinoid necrosis]] of the [[spiral]] [[vessel walls]] | *The formation of [[atheromatous plaques]] and [[fibrinoid necrosis]] of the [[spiral]] [[vessel walls]] | ||
* [[Oxidative stress]] in [[trophoblast cells]] | *[[Oxidative stress]] in [[trophoblast cells]] | ||
* [[Apoptosis]] in [[trophoblast cells]] | *[[Apoptosis]] in [[trophoblast cells]] | ||
* [[Systemic inflammatory response]] | *[[Systemic inflammatory response]] | ||
* [[Vasospasm]] | *[[Vasospasm]] | ||
* [[Platelet]] aggregation | *[[Platelet]] aggregation | ||
* [[Thrombin]] formation | *[[Thrombin]] formation | ||
* Deposition of the [[fibrin]] in multiple [[organs]] | *Deposition of the [[fibrin]] in multiple [[organs]] | ||
==Diagnosis== | ==Diagnosis== | ||
Shown below is an algorithm summarizing the diagnosis of [[Pre-eclampsia]]. | Shown below is an algorithm summarizing the diagnosis of [[Pre-eclampsia]].<br> | ||
<span style="font-size:85%"> | |||
'''Abbreviations:''' '''BP''': Blood pressure, '''RR'''=Respiratory rate, | |||
'''HR'''=Heart Rate, '''OCP'''= [[Oral contraceptive|Oral Contraceptive Pill]], '''P :Cr'''= [[Protein]]:[[Creatinine]], '''sFlt-1'''= Soluble fms-like tyrosine kinase 1 , '''PlGF'''= [[placental growth factor]], '''A:Cr'''= [[Albumin]] to [[Creatinine]] | |||
<br /> | |||
{{Family tree/start}} | {{Family tree/start}} | ||
{{Family tree | | | | | | | A01 | | | | | | | |A01= Pregnant woman comes with [[Hypertension]]}} | {{Family tree | | | | | | | A01 | | | | | | | |A01= [[Pregnant]] woman comes with [[Hypertension]]}} | ||
{{Family tree | | | | | | | |!| | | | | | | | |}} | {{Family tree | | | | | | | |!| | | | | | | | |}} | ||
{{Family tree | | | | | | | B01 | | | | | | | |B01= Take complete history}} | {{Family tree | | | | | | | B01 | | | | | | | |B01= Take complete history}} | ||
Line 54: | Line 78: | ||
{{Family tree | | | | | | | B02 | | | | | | | |B02= <div style="float: left; text-align: left;"> '''Take [[obstetric]] history :'''<br> | {{Family tree | | | | | | | B02 | | | | | | | |B02= <div style="float: left; text-align: left;"> '''Take [[obstetric]] history :'''<br> | ||
---- | ---- | ||
❑ Date of last [[menstrual]] period? <br><br>❑ Estimated date of [[delivery]]<br><br>❑ Confirm the [[gestational]] age, [[gravidity]] and [[parity]].<br><br> ❑ Check if this is a single or multiple [[gestation]].<br><br> </div>| | | | | | | |}} | ❑ Date of last [[menstrual]] period? <br><br>❑ Estimated date of [[delivery]].<br><br>❑ Confirm the [[gestational]] age, [[gravidity]] and [[parity]].<br><br> ❑ Check if this is a single or multiple [[gestation]].<br><br> </div>| | | | | | | |}} | ||
{{Family tree | | | | | | | |!| | | | | | | | |}} | {{Family tree | | | | | | | |!| | | | | | | | |}} | ||
{{Family tree | | | | | | | B01 | | | | | | | |B01= <div style="float: left; text-align: left;"> '''Ask about previous obstetric history if she was | {{Family tree | | | | | | | B01 | | | | | | | |B01= <div style="float: left; text-align: left;"> '''Ask about previous obstetric history if she was previously [[pregnant]] :'''<br> | ||
---- | ---- | ||
❑ Ask about previous pregnancies including [[miscarriages]] and [[Termination of pregnancy|terminations]]. <br><br>❑ Length of [[gestation]]. <br><br>❑ Ask about mode of delivery. <br><br>❑ Ask if there was similar complaints during previous [[pregnancy]]?<br><br>❑ Was there any complications throughout the [[pregnancy]] or during [[delivery]] such as [[shoulder dystocia]], [[postpartum haemorrhage]] ?<br><br></div>| | | | | | | | }} | ❑ Ask about previous pregnancies including [[miscarriages]] and [[Termination of pregnancy|terminations]]. <br><br>❑ Length of [[gestation]]. <br><br>❑ Ask about mode of delivery. <br><br>❑ Ask if there was similar complaints during previous [[pregnancy]]?<br><br>❑ Was there any complications throughout the [[pregnancy]] or during [[delivery]] such as [[shoulder dystocia]], [[postpartum haemorrhage]] ?<br><br></div>| | | | | | | | }} | ||
Line 74: | Line 98: | ||
❑ African-American race<br><br> </div>| | | | | | |}} | ❑ African-American race<br><br> </div>| | | | | | |}} | ||
{{Family tree | | | | | | | |!| | | | | | | | |}} | {{Family tree | | | | | | | |!| | | | | | | | |}} | ||
{{Family tree | | | | | | | B02 | | | | | | | |B02= <div style="float: left; text-align: left;"> '''Do laboratory tests<ref name="pmid29899139">{{cite journal |vauthors=Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S |title=Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice |journal=Hypertension |volume=72 |issue=1 |pages=24–43 |date=July 2018 |pmid=29899139 |doi=10.1161/HYPERTENSIONAHA.117.10803 |url= |issn=}}</ref>:'''<br> | {{Family tree | | | | | | | B02 | | | | | | | |B02= <div style="float: left; text-align: left;"> '''Do the following laboratory tests <ref name="pmid29899139">{{cite journal |vauthors=Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S |title=Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice |journal=Hypertension |volume=72 |issue=1 |pages=24–43 |date=July 2018 |pmid=29899139 |doi=10.1161/HYPERTENSIONAHA.117.10803 |url= |issn=}}</ref>:'''<br> | ||
---- | ---- | ||
❑ [[Dipstick]] testing<br><br>❑ If dipstick test is positive (one protein or more), the use of either spot urine albumin to creatinine (A:Cr) or protein to creatinine (P:Cr) ratios are recommended to quantify proteinuria.<ref name="urlOverview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE">{{cite web |url=https://www.nice.org.uk/guidance/ng133 |title=Overview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref><br><br>❑ [[Haemoglobin]]<br><br>❑ [[Platelet]] count<br><br>❑ Serum [[creatinine]]<br><br>❑ [[Liver enzymes]]<br><br>❑ Serum [[uric acid]] <br><br>❑ Use of PlGF or sFlt-1:PlGF ratio to help rule out [[preeclampsia]] in women between 20 and 34 + 6 | ❑ [[Dipstick]] testing<br><br>❑ If [[dipstick]] test is positive (one protein or more), the use of either spot [[urine]] [[albumin]] to [[creatinine]] (A:Cr) or [[protein]] to [[creatinine]] (P:Cr) ratios are recommended to quantify proteinuria.<ref name="urlOverview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE">{{cite web |url=https://www.nice.org.uk/guidance/ng133 |title=Overview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref><br><br>❑ [[Haemoglobin]]<br><br>❑ [[Platelet]] count<br><br>❑ Serum [[creatinine]]<br><br>❑ [[Liver enzymes]]<br><br>❑ Serum [[uric acid]] <br><br>❑ Use of [[PlGF]] or [[sFlt-1]]:[[PlGF]] ratio to help rule out [[preeclampsia]] in women between 20 and 34 + 6 weeks of gestation in whom [[preeclampsia]] is suspected.<ref name="pmid26735990">{{cite journal |vauthors=Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S |title=Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia |journal=N Engl J Med |volume=374 |issue=1 |pages=13–22 |date=January 2016 |pmid=26735990 |doi=10.1056/NEJMoa1414838 |url= |issn=}}</ref><br><br>❑ [[Ultrasound]] assessment of fetal growth and [[umbilical artery]] doppler velocimetry or cerebroplacental ratio measurements to assess blood flow redistribution in [[placental insufficiency]]. </div>| | | | | | | |}} | ||
{{Family tree | | | | | | | |!| | | | | | | | |}} | {{Family tree | | | | | | | |!| | | | | | | | |}} | ||
{{Family tree | | | | | | | B02 | | | | | | | |B02= <div style="float: left; text-align: left; "> '''[[PRE-ECLAMPSIA]]:Preeclampsia is defined as Gestational Hypertension associated with new-onset maternal or uteroplacental dysfunction at or after 20 | {{Family tree | | | | | | | B02 | | | | | | | |B02= <div style="float: left; text-align: left; "> '''[[PRE-ECLAMPSIA]]: [[Preeclampsia]] is defined as [[Gestational Hypertension]] associated with new-onset maternal or uteroplacental dysfunction at or after 20 Weeks of [[Gestation]]'''<br> | ||
---- | ---- | ||
❑ Gestational Hypertension : [[ | ❑ [[Gestational Hypertension]] : [[Blood pressure]] higher than 140/90 measured on two separate occasions, more than 6 hours apart.<ref name="pmid23403779">{{cite journal |vauthors=Lo JO, Mission JF, Caughey AB |title=Hypertensive disease of pregnancy and maternal mortality |journal=Curr Opin Obstet Gynecol |volume=25 |issue=2 |pages=124–32 |date=April 2013 |pmid=23403779 |doi=10.1097/GCO.0b013e32835e0ef5 |url= |issn=}}</ref><br><br> | ||
Accompanied by at ≥1 of the following new-onset conditions<ref name="pmid31590294">{{cite journal |vauthors=Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ |title=Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring |journal=J Clin Med |volume=8 |issue=10 |pages= |date=October 2019 |pmid=31590294 |pmc=6832549 |doi=10.3390/jcm8101625 |url= |issn=}}</ref>:<br><br> | Accompanied by at ≥1 of the following new-onset conditions<ref name="pmid31590294">{{cite journal |vauthors=Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ |title=Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring |journal=J Clin Med |volume=8 |issue=10 |pages= |date=October 2019 |pmid=31590294 |pmc=6832549 |doi=10.3390/jcm8101625 |url= |issn=}}</ref>:<br><br> | ||
❑ [[Proteinuria]]: | ❑ [[Proteinuria]]: Automated [[dipstick]] [[urinalysis]] should be done. If not available, visual analysis can be used. | ||
If [[dipstick]] is positive (≥1+), confirmation is done with spot [[urine]].<br> | If [[dipstick]] is positive (≥1+), confirmation is done with spot [[urine]].<br> | ||
Abnormal if [[Protein]]:[[Creatinine]] ≥ 30 mg/mmol or [[Albumin]]:[[Creatinine]] ≥ 8 mg/mmol.<ref name="pmid16020501">{{cite journal |vauthors=Price CP, Newall RG, Boyd JC |title=Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review |journal=Clin Chem |volume=51 |issue=9 |pages=1577–86 |date=September 2005 |pmid=16020501 |doi=10.1373/clinchem.2005.049742 |url= |issn=}}</ref><ref name="pmid28647444">{{cite journal |vauthors=Kucukgoz Gulec U, Sucu M, Ozgunen FT, Buyukkurt S, Guzel AB, Paydas S |title=Spot Urine Protein-to-Creatinine Ratio to Predict the Magnitude of 24-Hour Total Proteinuria in Preeclampsia of Varying Severity |journal=J Obstet Gynaecol Can |volume=39 |issue=10 |pages=854–860 |date=October 2017 |pmid=28647444 |doi=10.1016/j.jogc.2017.04.035 |url= |issn=}}</ref><br><br> | Abnormal if [[Protein]]:[[Creatinine]] ≥ 30 mg/mmol or [[Albumin]]:[[Creatinine]] ≥ 8 mg/mmol.<ref name="pmid16020501">{{cite journal |vauthors=Price CP, Newall RG, Boyd JC |title=Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review |journal=Clin Chem |volume=51 |issue=9 |pages=1577–86 |date=September 2005 |pmid=16020501 |doi=10.1373/clinchem.2005.049742 |url= |issn=}}</ref><ref name="pmid28647444">{{cite journal |vauthors=Kucukgoz Gulec U, Sucu M, Ozgunen FT, Buyukkurt S, Guzel AB, Paydas S |title=Spot Urine Protein-to-Creatinine Ratio to Predict the Magnitude of 24-Hour Total Proteinuria in Preeclampsia of Varying Severity |journal=J Obstet Gynaecol Can |volume=39 |issue=10 |pages=854–860 |date=October 2017 |pmid=28647444 |doi=10.1016/j.jogc.2017.04.035 |url= |issn=}}</ref><br><br> | ||
Line 88: | Line 112: | ||
❑ [[Liver]] complications: Elevated [[transaminases]], may be associated with right upper quadrant of [[epigastric]] [[abdominal pain]].<br><br> | ❑ [[Liver]] complications: Elevated [[transaminases]], may be associated with right upper quadrant of [[epigastric]] [[abdominal pain]].<br><br> | ||
❑ [[Neurological]] complications: [[Eclampsia]], [[altered mental status]], [[blindness]], [[stroke]], [[clonus]], severe and persistent visual [[Scotoma|scotomata]].<br><br> | ❑ [[Neurological]] complications: [[Eclampsia]], [[altered mental status]], [[blindness]], [[stroke]], [[clonus]], severe and persistent visual [[Scotoma|scotomata]].<br><br> | ||
❑ [[Haematological]] complications: [[Thrombocytopenia]] (platelet count < 150000/µL, [[disseminated intravascular coagulation]], [[hemolysis]]).<br><br> | ❑ [[Haematological]] complications: [[Thrombocytopenia]] ([[platelet]] count < 150000/µL, [[disseminated intravascular coagulation]], [[hemolysis]]).<br><br> | ||
❑ [[Uteroplacental]] dysfunction: Fetal [[growth]] restriction, abnormal [[umbilical artery]] [[doppler]] wave form analysis, [[stillbirth]].<br><br> | ❑ [[Uteroplacental]] dysfunction: Fetal [[growth]] restriction, abnormal [[umbilical artery]] [[doppler]] wave form analysis, [[stillbirth]].<br><br> | ||
</div>| | | | | | | |}} | </div>| | | | | | | |}} | ||
Line 97: | Line 121: | ||
==Treatment== | ==Treatment== | ||
Shown below is an algorithm summarizing the treatment of mild hypertension and [[preeclampsia]]. | Shown below is an algorithm summarizing the treatment of mild [[hypertension]] and [[preeclampsia]].<ref name="urlpqcnc-documents.s3.amazonaws.com">{{cite web |url=https://pqcnc-documents.s3.amazonaws.com/cmop/cmopresources/PQCNCCMOPDiagnosis.pdf |title=pqcnc-documents.s3.amazonaws.com |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | ||
<span style="font-size:85%"> | |||
'''Abbreviations:''' IV: Intravenous, '''IM'''= Intramuscular, '''IUGR'''= intrauterine growth restriction | |||
<br /> | |||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
{{familytree | | | | | | | | A01 |A01= Woman with mild [[hypertension]] and [[preeclampsia]]}} | {{familytree | | | | | | | | A01 |A01= Woman with mild [[hypertension]] and [[preeclampsia]]<ref name="urlPreeclampsia And Eclampsia - Harvard Health">{{cite web |url=https://www.health.harvard.edu/a_to_z/preeclampsia-and-eclampsia-a-to-z |title=Preeclampsia And Eclampsia - Harvard Health |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref><div class="mw-collapsible mw-collapsed";><div style="float: left; text-align: left; ">Characterized by the following: | ||
❑ Blood pressure of 140/90 or above<br><br> | |||
❑ Swelling, particularly of the arms, hands, or face that is reflected in greater than expected [[weight]] gain, which is a result of retaining fluid. (Swelling in the ankle area is considered normal during [[pregnancy]].)<br><br> | |||
❑ [[Protein]] in the [[urine]]. Although uncommon, a woman can have preeclampsia without protein in the [[urine]].<br><br>}} | |||
{{familytree | | | | | | | | |!| | | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | | }} | ||
{{familytree | | | | | | | | A01 |A01= Evaluate maternal and fetal condition}} | {{familytree | | | | | | | | A01 |A01= Evaluate [[maternal]] and [[fetal]] condition}} | ||
{{familytree | | | | | | | | |!| | | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | | }} | ||
{{familytree | | | | | | | | A01 |-|-|l01|-|o01| | |A01= <div style="float: left; text-align: left; "> | {{familytree | | | | | | | | A01 |-|-|l01|-|o01| | |A01= <div style="float: left; text-align: left; "> | ||
<br> | <br> | ||
❑ ≥40 weeks of [[gestation]]. <br><br> ❑ ≥ 37 weeks of [[gestation]], [[Bishop score]] ≥ 6, non-complaint patient<br><br> ❑ ≥34 weeks gestation, [[ | ❑ ≥40 weeks of [[gestation]]. <br><br> ❑ ≥ 37 weeks of [[gestation]], [[Bishop score]] ≥ 6, non-complaint patient.<br><br> ❑ ≥34 weeks gestation, [[labor]] or rupture of [[membranes]], abnormal [[fetal]] testing, [[intrauterine]] growth restriction. <br><br></div>|l01= Yes|o01= [[Delivery]] |}} | ||
{{familytree | | | | | | | | |!| | | | | | | | | |!| | }} | {{familytree | | | | | | | | |!| | | | | | | | | |!| | }} | ||
{{familytree | | | | | | | | A01 | | | | | | | | |!||A01= No}} | {{familytree | | | | | | | | A01 | | | | | | | | |!||A01= No}} | ||
Line 116: | Line 146: | ||
{{familytree | | | | | | | | |!| | | | | | | | | |!| | }} | {{familytree | | | | | | | | |!| | | | | | | | | |!| | }} | ||
{{familytree | | | | | | | | A01 | | | | | | | | p01 | |p01='''<big>↑</big>'''|A01= <div style="float: left; text-align: left; "> | {{familytree | | | | | | | | A01 | | | | | | | | p01 | |p01='''<big>↑</big>'''|A01= <div style="float: left; text-align: left; "> | ||
❑ Fetal and maternal monitoring on a regular basis <br>❑ Inpatient and outpatient management <br></div> }} | ❑ Fetal and maternal monitoring on a regular basis. <br>❑ Inpatient and outpatient management. <br></div> }} | ||
{{familytree | | | | | | | | |!| | | | | | | | | |!| | }} | {{familytree | | | | | | | | |!| | | | | | | | | |!| | }} | ||
{{familytree | | | | | | | | A01 |-|-|u01|-|-|-|'||A01=<div style="float: left; text-align: left; "> | {{familytree | | | | | | | | A01 |-|-|u01|-|-|-|'||A01=<div style="float: left; text-align: left; "> | ||
❑ Worsening [[fetal]] and [[maternal]] condition <br> ❑ ≥40 weeks of [[gestation]] <br>❑ Bishop score ≥ 6 at ≥ 37 weeks of gestation.<br>❑ [[Labor]]</div>||u01=<big>'''→'''</big> }} | ❑ Worsening [[fetal]] and [[maternal]] condition. <br> ❑ ≥40 weeks of [[gestation]] <br>❑ Bishop score ≥ 6 at ≥ 37 weeks of gestation.<br>❑ [[Labor]]</div>||u01=<big>'''→'''</big> }} | ||
{{familytree/end}} | {{familytree/end}} | ||
Shown below is an algorithm summarizing the treatment of severe [[preeclampsia]]. | Shown below is an algorithm summarizing the treatment of severe [[preeclampsia]].<ref name="urlpqcnc-documents.s3.amazonaws.com">{{cite web |url=https://pqcnc-documents.s3.amazonaws.com/cmop/cmopresources/PQCNCCMOPDiagnosis.pdf |title=pqcnc-documents.s3.amazonaws.com |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref><ref name="urlPreeclampsia And Eclampsia - Harvard Health">{{cite web |url=https://www.health.harvard.edu/a_to_z/preeclampsia-and-eclampsia-a-to-z |title=Preeclampsia And Eclampsia - Harvard Health |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | ||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
{{familytree | | | | | | | | A01 |A01= Woman with severe [[pre eclampsia]]}} | {{familytree | | | | | | | | A01 |A01= Woman with severe [[pre eclampsia]]<ref name="urlPreeclampsia And Eclampsia - Harvard Health">{{cite web |url=https://www.health.harvard.edu/a_to_z/preeclampsia-and-eclampsia-a-to-z |title=Preeclampsia And Eclampsia - Harvard Health |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref><div class="mw-collapsible mw-collapsed";><div style="float: left; text-align: left; "> | ||
Characterized by:<br><br> | |||
❑ Blood pressure of 160/110 mmHg or higher in more than one reading separated by at least six hours.<br><br> | |||
❑ Proteinuria<br><br> | |||
Or | |||
❑ [[Blood pressure]] of 140/90 mmHg or higher. <br><br> | |||
❑ Symptoms or signs of ongoing damage to internal [[organs]], such as: | |||
Severe [[headache]], changes in [[vision]], reduced [[urine output]], [[abdominal pain]], fluid in the [[lungs]] and [[pelvic]] [[pain]].<br><br> | |||
❑ Signs of the "[[HELLP syndrome|HELLP]]" syndrome, which means the liver and [[Blood clotting|blood-clotting]] systems are not functioning properly. [[HELLP syndrome|HELLP]] stands for [[Hemolysis]] (damaged red blood cells), Elevated [[Liver]] [[enzymes]] (indicating ongoing [[liver]] cell damage) and Low [[Platelets]] that help the [[blood]] to [[clot]]. It occurs in about 10% of patients with severe [[preeclampsia]].}} | |||
{{familytree | | | | | | | | |!| | | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | | }} | ||
{{familytree | | | | | | | | B01 | | | B01=<div style="float: left; text-align: left;"> | {{familytree | | | | | | | | B01 | | | B01=<div style="float: left; text-align: left;"> | ||
<br> | <br> | ||
❑ Admit to the [[labor]] and [[delivery]] unit. <br><br> ❑ Evaluate maternal and fetal condition for 24 hours.<br><br> ❑ Administer [[Magnesium sulphate]] X 24 hours.<br><br> ❑ Anti-hypertensives if [[systolic blood pressure]] ≥ 160mm Hg, [[diastolic blood pressure]] ≥110 mmHg and meant aretrial blood pressure ≥125 mmHg<br><br> </div> }} | ❑ Admit to the [[labor]] and [[delivery]] unit. <br><br> ❑ Evaluate [[maternal]] and [[fetal]] condition for 24 hours.<br><br> ❑ Administer [[Magnesium sulphate]] X 24 hours.<br><br> ❑ Anti-hypertensives if [[systolic blood pressure]] ≥ 160mm Hg, [[diastolic blood pressure]] ≥110 mmHg and meant aretrial blood pressure ≥125 mmHg.<br><br> </div> }} | ||
{{familytree | | | | | | | | |!| | | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | | }} | ||
{{familytree | | | | | | | | B01 | | | | | | | |B01=<div style="float: left; text-align: left; "> Check if following are present:<br> | {{familytree | | | | | | | | B01 | | | | | | | |B01=<div style="float: left; text-align: left; "> Check if following are present:<br> | ||
Line 159: | Line 198: | ||
{{familytree | | | | | | | | | | | | | | | | | | p01| |o01| |p01=<div style="float: left; text-align: left; "> | {{familytree | | | | | | | | | | | | | | | | | | p01| |o01| |p01=<div style="float: left; text-align: left; "> | ||
<br> | <br> | ||
❑ Steroids at 24-32 weeks <br><br> ❑ [[Anti-hypertensives]] if required.<br><br> ❑ Daily maternal and fetal evaluation.<br><br> ❑ Delivery at 34 weeks. <br><br></div>|o01= termination of [[pregnancy ]]| |}} | ❑ Steroids at 24-32 weeks <br><br> ❑ [[Anti-hypertensives]] if required.<br><br> ❑ Daily [[maternal]] and [[fetal]] evaluation.<br><br> ❑ [[Delivery]] at 34 weeks. <br><br></div>|o01= termination of [[pregnancy ]]| |}} | ||
{{familytree/end}} | {{familytree/end}} | ||
== | {| class="wikitable" | ||
* | |- | ||
! align="center" style="background: #4479BA; color: #FFFFFF " |Drugs for urgent controlling of [[hypertension]] in [[preeclampsia]]<ref>{{cite journal|title=Gestational Hypertension and Preeclampsia|journal=Obstetrics & Gynecology|volume=135|issue=6|year=2020|pages=e237–e260|issn=0029-7844|doi=10.1097/AOG.0000000000003891}}</ref> | |||
! align="center" style="background: #4479BA; color: #FFFFFF " |Dose!! align="center" style="background: #4479BA; color: #FFFFFF " |Specific considration!! align="center" style="background: #4479BA; color: #FFFFFF " |Onset of action | |||
|- | |||
|[[Labetalol]]||❑ 10–20 mg IV<br><br> | |||
❑ Then 20–80 mg every 10–30 minutes upto a maximum dosage of 300 mg;or infusion 1–2 mg/min IV | |||
|Contraindications: | |||
*[[Asthma]] | |||
*[[Decompensated heart failure]], | |||
*[[ Heart block]] | |||
*[[Bradycardia]] | |||
||1-2 minutes | |||
|- | |||
|[[Hydralazine]]||❑ 5 mg IV or IM<br><br>❑ Then 5–10 mg IV every 20–40 minutes upto a maximum dosage of 200 mg or keeping infusion of 0.5–10 mg/hr.||Side effects in higher dosage: | |||
*maternal [[hypotension]] | |||
*[[Headaches]] | |||
*Abnormal [[fetal heart rate]] tracings | |||
||10-20 minutes | |||
|- | |||
|[[Nifedipine]]||❑ 10–20 mg orally, repeat in 20 minutes if needed .<br><br>❑ Then 10–20 mg every 2–6 hours, maximum daily dose is 180 mg.||Side effect: | |||
*Reflex [[tachycardia]] | |||
*[[Headache]] | |||
||5-10 minutes | |||
|- | |||
|} | |||
==Dos== | |||
*Patient should start low-dose [[aspirin]] if she has two or more moderate risk factors. | |||
*If a woman had [[preeclampsia]] during a previous [[pregnancy]], the patient should maintain a healthy weight and make sure other conditions such as [[diabetes]], are well managed before getting [[pregnant]]. | |||
*Once a woman is [[pregnant]] with history of previous [[preeclampsia]], the patient should complete early and regular prenatal care visits. | |||
*If a [[pregnant]] woman has [[swelling]], severe [[headache]], changes in [[vision]] or other symptoms of [[preeclampsia]], she should contact the doctor immediately. | |||
*It is important to start leading a healthy lifestyle which includes maintaining a healthy [[weight]], exercising regularly, eating a well-balanced [[diet]], not smoking or not using alcohol. | |||
==Don'ts== | ==Don'ts== | ||
* | |||
*It's important that a pregnant woman does not take any medications, vitamins or supplements without first talking to her doctor. | |||
==References== | ==References== | ||
Line 178: | Line 253: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] |
Latest revision as of 13:14, 15 April 2021
Preeclampsia Resident Survival Guide Microchapters |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Dos |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rinky Agnes Botleroo, M.B.B.S.
Synonyms and keywords: Approach to preeclampsia , Approach to gestational hypertension with proteinuria
Overview
Preeclampsia is primarily defined as gestational hypertension with proteinuria 300 mg or more over a 24-hour period. The pathophysiologic abnormalities of preeclampsia include placental ischemia, generalized vasospasm, abnormal hemostasis with activation of the coagulation system, vascular endothelial dysfunction, abnormal nitric oxide and lipid metabolism, leukocyte activation and changes in various cytokines as well as in insulin resistance. It is important to identify those with high risk of developing preeclampsia during their pregnancy for better management. Maternal and fetal outcomes in preeclampsia depend on one or more of these factors: gestational age at onset of preeclampsia as well as at time of delivery, the severity of the disease process, the presence of multifetal gestation, and the presence of other preexisting medical conditions such as diabetes, renal disease, or thrombophilias. It is associated with an increased risk of placental abruption, preterm birth, fetal intrauterine growth restriction (IUGR), acute renal failure, cerebrovascular and cardiovascular complications, disseminated intravascular coagulation, and maternal death. Therefore, it is necessary to diagnose preeclampsia early.
Causes
The high risk factors of preeclampsia are:
- History of any hypertensive disease during a previous pregnancy.
- Maternal disease such as chronic kidney disease, autoimmune diseases, diabetes, chronic hypertension.
Women are at moderate risk if they are:
- Nulliparous
- ≥40 years of age
- Have a Body mass index (BMI) ≥ 35 kg/m [1]
- Have a family history of preeclampsia
- Have a Multifetal pregnancy
- Have a A pregnancy interval of more than 10 years[2]
Additional clinical factors associated with preeclampsia are :
- Raised mean arterial blood pressure before 15 weeks gestation[3]
- Polycystic ovarian syndrome[4][5]
- Sleep disordered breathing [6]
- Various infections such as periodontal disease,urinary tract infections[7] and helicobacter pylori[8].
- Vaginal bleeding for at least five days during pregnancy increases preeclampsia risk[3]
- Use of oocyte donation has a higher risk of preeclampsia than in vitro fertilization (IVF) without oocyte donation or natural conception.[9][10]
Common Causes
Common causes of preeclampsia include uteroplacental ischemia and genetic predisposition due to the following:[11][12]
- The formation of atheromatous plaques and fibrinoid necrosis of the spiral vessel walls
- Oxidative stress in trophoblast cells
- Apoptosis in trophoblast cells
- Systemic inflammatory response
- Vasospasm
- Platelet aggregation
- Thrombin formation
- Deposition of the fibrin in multiple organs
Diagnosis
Shown below is an algorithm summarizing the diagnosis of Pre-eclampsia.
Abbreviations: BP: Blood pressure, RR=Respiratory rate,
HR=Heart Rate, OCP= Oral Contraceptive Pill, P :Cr= Protein:Creatinine, sFlt-1= Soluble fms-like tyrosine kinase 1 , PlGF= placental growth factor, A:Cr= Albumin to Creatinine
Pregnant woman comes with Hypertension | |||||||||||||||||||||||||||||||||||||||||||||||
Take complete history | |||||||||||||||||||||||||||||||||||||||||||||||
Ask about previous obstetric history if she was previously pregnant : ❑ Ask about previous pregnancies including miscarriages and terminations. ❑ Length of gestation. ❑ Ask about mode of delivery. ❑ Ask if there was similar complaints during previous pregnancy? ❑ Was there any complications throughout the pregnancy or during delivery such as shoulder dystocia, postpartum haemorrhage ? | |||||||||||||||||||||||||||||||||||||||||||||||
Ask the following questions about menstrual history : ❑ Age of menarche ❑ Last menstrual period ❑ Is the menstrual flow normal? How many pads she has to use in a day? ❑ Is there any foul smell or colour change? ❑ How many days does the menstruation stay? ❑ Contraceptive history for example oral contraceptives, intrauterine device | |||||||||||||||||||||||||||||||||||||||||||||||
See if following factors are present: ❑ History of hypertension | |||||||||||||||||||||||||||||||||||||||||||||||
Do the following laboratory tests [1]: ❑ Dipstick testing ❑ If dipstick test is positive (one protein or more), the use of either spot urine albumin to creatinine (A:Cr) or protein to creatinine (P:Cr) ratios are recommended to quantify proteinuria.[2] ❑ Haemoglobin ❑ Platelet count ❑ Serum creatinine ❑ Liver enzymes ❑ Serum uric acid ❑ Use of PlGF or sFlt-1:PlGF ratio to help rule out preeclampsia in women between 20 and 34 + 6 weeks of gestation in whom preeclampsia is suspected.[13] ❑ Ultrasound assessment of fetal growth and umbilical artery doppler velocimetry or cerebroplacental ratio measurements to assess blood flow redistribution in placental insufficiency. | |||||||||||||||||||||||||||||||||||||||||||||||
PRE-ECLAMPSIA: Preeclampsia is defined as Gestational Hypertension associated with new-onset maternal or uteroplacental dysfunction at or after 20 Weeks of Gestation ❑ Gestational Hypertension : Blood pressure higher than 140/90 measured on two separate occasions, more than 6 hours apart.[14] | |||||||||||||||||||||||||||||||||||||||||||||||
Treatment
Shown below is an algorithm summarizing the treatment of mild hypertension and preeclampsia.[18]
Abbreviations: IV: Intravenous, IM= Intramuscular, IUGR= intrauterine growth restriction
Woman with mild hypertension and preeclampsia[19] Characterized by the following:
❑ Blood pressure of 140/90 or above | |||||||||||||||||||||||||||||||||||||||||||||
Evaluate maternal and fetal condition | |||||||||||||||||||||||||||||||||||||||||||||
❑ ≥ 37 weeks of gestation, Bishop score ≥ 6, non-complaint patient. ❑ ≥34 weeks gestation, labor or rupture of membranes, abnormal fetal testing, intrauterine growth restriction. | Yes | Delivery | |||||||||||||||||||||||||||||||||||||||||||
No | |||||||||||||||||||||||||||||||||||||||||||||
↑ | |||||||||||||||||||||||||||||||||||||||||||||
<37 weeks | 37-39 weeks | → | Prostaglandin | ||||||||||||||||||||||||||||||||||||||||||
❑ Fetal and maternal monitoring on a regular basis. ❑ Inpatient and outpatient management. | ↑ | ||||||||||||||||||||||||||||||||||||||||||||
→ | |||||||||||||||||||||||||||||||||||||||||||||
Shown below is an algorithm summarizing the treatment of severe preeclampsia.[18][19]
Woman with severe pre eclampsia[19] Characterized by: ❑ Blood pressure of 140/90 mmHg or higher. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Evaluate maternal and fetal condition for 24 hours. ❑ Administer Magnesium sulphate X 24 hours. ❑ Anti-hypertensives if systolic blood pressure ≥ 160mm Hg, diastolic blood pressure ≥110 mmHg and meant aretrial blood pressure ≥125 mmHg. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Check if following are present: --- ❑ Maternal distress❑ Non-reassuring fetal status. ❑ Labor or rupture of membranes. ❑ >34 weeks of gestation. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
↑ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Severe intrauterine growth restriction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
← | Steroids | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
↑ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
← | 33-34 weeks of gestation | 23-32 weeks of gestation | <23 weeks of gestation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Anti-hypertensives if required. ❑ Daily maternal and fetal evaluation. ❑ Delivery at 34 weeks. | termination of pregnancy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drugs for urgent controlling of hypertension in preeclampsia[20] | Dose | Specific considration | Onset of action |
---|---|---|---|
Labetalol | ❑ 10–20 mg IV ❑ Then 20–80 mg every 10–30 minutes upto a maximum dosage of 300 mg;or infusion 1–2 mg/min IV |
Contraindications: | 1-2 minutes |
Hydralazine | ❑ 5 mg IV or IM ❑ Then 5–10 mg IV every 20–40 minutes upto a maximum dosage of 200 mg or keeping infusion of 0.5–10 mg/hr. |
Side effects in higher dosage:
|
10-20 minutes |
Nifedipine | ❑ 10–20 mg orally, repeat in 20 minutes if needed . ❑ Then 10–20 mg every 2–6 hours, maximum daily dose is 180 mg. |
Side effect:
|
5-10 minutes |
Dos
- Patient should start low-dose aspirin if she has two or more moderate risk factors.
- If a woman had preeclampsia during a previous pregnancy, the patient should maintain a healthy weight and make sure other conditions such as diabetes, are well managed before getting pregnant.
- Once a woman is pregnant with history of previous preeclampsia, the patient should complete early and regular prenatal care visits.
- If a pregnant woman has swelling, severe headache, changes in vision or other symptoms of preeclampsia, she should contact the doctor immediately.
- It is important to start leading a healthy lifestyle which includes maintaining a healthy weight, exercising regularly, eating a well-balanced diet, not smoking or not using alcohol.
Don'ts
- It's important that a pregnant woman does not take any medications, vitamins or supplements without first talking to her doctor.
References
- ↑ 1.0 1.1 Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S (July 2018). "Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice". Hypertension. 72 (1): 24–43. doi:10.1161/HYPERTENSIONAHA.117.10803. PMID 29899139.
- ↑ 2.0 2.1 "Overview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE".
- ↑ 3.0 3.1 North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC (April 2011). "Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort". BMJ. 342: d1875. doi:10.1136/bmj.d1875. PMC 3072235. PMID 21474517.
- ↑ Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, Misso ML, Teede HJ, Moran LJ (May 2019). "Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression". Obes Rev. 20 (5): 659–674. doi:10.1111/obr.12829. PMID 30674081.
- ↑ Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY (June 2013). "Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis". Reprod Biol Endocrinol. 11: 56. doi:10.1186/1477-7827-11-56. PMC 3737012. PMID 23800002.
- ↑ Pamidi S, Pinto LM, Marc I, Benedetti A, Schwartzman K, Kimoff RJ (January 2014). "Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis". Am J Obstet Gynecol. 210 (1): 52.e1–52.e14. doi:10.1016/j.ajog.2013.07.033. PMID 23911687.
- ↑ Rustveld LO, Kelsey SF, Sharma R (March 2008). "Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies". Matern Child Health J. 12 (2): 223–42. doi:10.1007/s10995-007-0224-1. PMID 17577649.
- ↑ Bellos I, Daskalakis G, Pergialiotis V (February 2018). "Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies". Int J Clin Pract. 72 (2). doi:10.1111/ijcp.13064. PMID 29388723.
- ↑ Blázquez A, García D, Rodríguez A, Vassena R, Figueras F, Vernaeve V (July 2016). "Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis". J Assist Reprod Genet. 33 (7): 855–63. doi:10.1007/s10815-016-0701-9. PMC 4930777. PMID 27007875.
- ↑ Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D (March 2016). "Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis". Am J Obstet Gynecol. 214 (3): 328–39. doi:10.1016/j.ajog.2015.11.020. PMID 26627731.
- ↑ Lye, P.; Bloise, E.; Dunk, C.; Javam, M.; Gibb, W.; Lye, S.J.; Matthews, S.G. (2013). "Effect of oxygen on multidrug resistance in the first trimester human placenta". Placenta. 34 (9): 817–823. doi:10.1016/j.placenta.2013.05.010. ISSN 0143-4004.
- ↑ Mayrink, J.; Costa, M. L.; Cecatti, J. G. (2018). "Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction". The Scientific World Journal. 2018: 1–9. doi:10.1155/2018/6268276. ISSN 2356-6140.
- ↑ Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S (January 2016). "Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia". N Engl J Med. 374 (1): 13–22. doi:10.1056/NEJMoa1414838. PMID 26735990.
- ↑ Lo JO, Mission JF, Caughey AB (April 2013). "Hypertensive disease of pregnancy and maternal mortality". Curr Opin Obstet Gynecol. 25 (2): 124–32. doi:10.1097/GCO.0b013e32835e0ef5. PMID 23403779.
- ↑ Fox R, Kitt J, Leeson P, Aye C, Lewandowski AJ (October 2019). "Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring". J Clin Med. 8 (10). doi:10.3390/jcm8101625. PMC 6832549 Check
|pmc=
value (help). PMID 31590294. Vancouver style error: initials (help) - ↑ Price CP, Newall RG, Boyd JC (September 2005). "Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review". Clin Chem. 51 (9): 1577–86. doi:10.1373/clinchem.2005.049742. PMID 16020501.
- ↑ Kucukgoz Gulec U, Sucu M, Ozgunen FT, Buyukkurt S, Guzel AB, Paydas S (October 2017). "Spot Urine Protein-to-Creatinine Ratio to Predict the Magnitude of 24-Hour Total Proteinuria in Preeclampsia of Varying Severity". J Obstet Gynaecol Can. 39 (10): 854–860. doi:10.1016/j.jogc.2017.04.035. PMID 28647444.
- ↑ 18.0 18.1 "pqcnc-documents.s3.amazonaws.com" (PDF).
- ↑ 19.0 19.1 19.2 "Preeclampsia And Eclampsia - Harvard Health".
- ↑ "Gestational Hypertension and Preeclampsia". Obstetrics & Gynecology. 135 (6): e237–e260. 2020. doi:10.1097/AOG.0000000000003891. ISSN 0029-7844.